دورية أكاديمية
IL8 polymorphisms and overall survival in pazopanib- or sunitinib-treated patients with renal cell carcinoma.
| العنوان: | IL8 polymorphisms and overall survival in pazopanib- or sunitinib-treated patients with renal cell carcinoma. |
|---|---|
| المؤلفون: | Xu, C-F, Johnson, T, Garcia-Donas, J, Choueiri, TK, Sternberg, CN, Davis, ID, Bing, N, Deen, KC, Xue, Z, McCann, L, Esteban, E, Whittaker, JC, Spraggs, CF, Rodríguez-Antona, C, Pandite, LN, Motzer, RJ |
| بيانات النشر: | Springer Nature [academic journals on nature.com] |
| سنة النشر: | 2015 |
| المجموعة: | London School of Hygiene & Tropical Medicine: LSHTM Research Online |
| الوصف: | BACKGROUND: We evaluated germline single nucleotide polymorphisms (SNPs) for association with overall survival (OS) in pazopanib- or sunitinib-treated patients with advanced renal cell carcinoma (aRCC). METHODS: The discovery analysis tested 27 SNPs within 13 genes from a phase III pazopanib trial (N=241, study 1). Suggestive associations were then pursued in two independent datasets: a phase III trial (COMPARZ) comparing pazopanib vs sunitinib (N=729, study 2) and an observational study of sunitinib-treated patients (N=89, study 3). RESULTS: In study 1, four SNPs showed nominally significant association (P≤0.05) with OS; two of these SNPs (rs1126647, rs4073) in IL8 were associated (P≤0.05) with OS in study 2. Because rs1126647 and rs4073 were highly correlated, only rs1126647 was evaluated in study 3, which also showed association (P≤0.05). In the combined data, rs1126647 was associated with OS after conservative multiple-test adjustment (P=8.8 × 10(-5); variant vs reference allele hazard ratio 1.32, 95% confidence interval: 1.15-1.52), without evidence for heterogeneity of effects between studies or between pazopanib- and sunitinib-treated patients. CONCLUSIONS: Variant alleles of IL8 polymorphisms are associated with poorer survival outcomes in pazopanib- or sunitinib-treated patients with aRCC. These findings provide insight in aRCC prognosis and may advance our thinking in development of new therapies. |
| نوع الوثيقة: | article in journal/newspaper |
| وصف الملف: | text |
| اللغة: | English |
| العلاقة: | https://researchonline.lshtm.ac.uk/id/eprint/2293414/1/bjc201564a.pdfTest; Xu, C-F; Johnson, T; Garcia-Donas, J; Choueiri, TK; Sternberg, CN; Davis, ID; Bing, N; Deen, KC; Xue, Z; McCann, L; +6 more. Esteban, E; Whittaker, JC ; Spraggs, CF; Rodríguez-Antona, C; Pandite, LN; Motzer, RJ; (2015) IL8 polymorphisms and overall survival in pazopanib- or sunitinib-treated patients with renal cell carcinoma. British journal of cancer, 112 (7). pp. 1190-1198. ISSN 0007-0920 DOI: https://doi.org/10.1038/bjc.2015.64Test |
| الإتاحة: | https://doi.org/10.1038/bjc.2015.64Test https://researchonline.lshtm.ac.uk/id/eprint/2293414Test/ https://researchonline.lshtm.ac.uk/id/eprint/2293414/1/bjc201564a.pdfTest |
| حقوق: | cc_by_nc_sa |
| رقم الانضمام: | edsbas.5768893 |
| قاعدة البيانات: | BASE |
| الوصف غير متاح. |